Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: The Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973

Optometry

Volumn 82, Issue 11, 2011, Pages

  Richer, Stuart P ^a,b   Stiles, William ^a   Graham Hoffman, Kelly ^a   Levin, Marc ^a   Ruskin, Dennis ^c   Wrobel, James ^b   Park, Dong Wouk ^b   Thomas, Carla ^a  

^a Captain James A Lovell Federal Health Care Facility   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c NONE

Author keywords

Atrophic age related macular degeneration; Carotenoids; Lutein; Macular pigment; Zeaxanthin

Indexed keywords

EID: 82455171789     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.optm.2011.08.008     Document Type: Article

References (71)

1. Richer S.P. Is there a prevention and treatment strategy for age related macular degeneration?. J Am Optom Assoc 1993, 64:838-850.
2. Multicenter ophthalmic and nutritional age-related macular degeneration study-Part 1: Design, subjects and procedures. J Am Optom Assoc 1996, 67:12-29. Age-Related Macular Degeneration Study Group.
3. Multicenter ophthalmic and nutritional age-related macular degeneration study-part 2: antioxidant intervention & conclusions. J Am Optom Assoc 1996, 67:30-49. Age-Related Macular Degeneration Study Group.
4. Richer S.P. Antioxidants and the eye. International Ophthalmology Clinics 2000, vol 40:1-16. CRC Press, Philadelphia. M.H. Friedlaender (Ed.).
5. A randomized placebo-controlled clinical trial of high-dosed supplementation with vitamins C and E, beta carotene, and zinc for age related macular degeneration and vision loss, AREDS Report No. 8. Arch Ophthalmol 2001, 119:1417-1436. Age-Related Eye Disease Research Group.
6. Richer S.P. A protocol for the evaluation and treatment of atrophic age-related macular degeneration. J Am Optom Assoc 1999, 70:13-23.
7. Richer S.P. ARMD-pilot (case studies) environmental intervention data. J Am Optom Assoc 1999, 70:24-26.
8. Richer S.P., Stiles W., Statkute L., et al. A placebo-controlled, double blind, randomized trial of lutein and antioxidant supplementation for the treatment of age related macular degeneration: the Lutein Antioxidant Supplementation Trial. Optometry 2004, 75:216-230.
9. Neelam K., Nolan J., Chakravarthy U., et al. Psychophysical function in age-related maculopathy. Surv Ophthalmol 2009, 54:167-210.
10. Feher J., Kovacs B., Kovacs I., et al. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica 2005, 219:154-166.
11. Schalch W., Cohn W., Barker F.M., et al. Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin-the LUXEA Study (Lutein Xanthophyll Accumulation Study). Arch Biochem Biophys 2006, 458:128-135.
12. Trieschmann M., Beatty S., Nolan J.M., et al. Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA Study. Exp Eye Res 2007, 84:718-728.
13. Cangemi F.E. TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmol 2007, 7:3.
14. Parisi V., Tedeschi M., Gallinaro G., et al. Carotenoids and antioxidants in age-related maculopathy Italian study: multifocal electroretinogram modifications after 1 year. Ophthalmology 2008, 115:324-333. The CARMIS Study Group.
15. Neelam K., Hogg R.E., Stevenson M.R., et al. CARMA Study: Carotenoids and co-antioxidants in age-related maculopathy: design and methods. Ophthalmic Epidemiol 2008, 15:389-401.
16. Bernstein P.S., Delori F.C., Richer S., et al. The value of measurement of macular carotenoid pigment optical densities and distributions in age-related macular degeneration and other retinal disorders. Vis Res 2010, 50:716-728.
17. National Eye Institute. Age-Related Eye Disease Study 2 (AREDS2). Available at: Last accessed December 26, 2010. http://www.nei.nih.gov/areds2/.
18. Bone R.A., Landrum J.T., Mayne S.T., et al. Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci 2001, 42:235-240.
19. Bone R.A., Landrum J.T., Guerra L.H., et al. Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr 2003, 133:1953.
20. Bone R.A., Landrum J.T. Dose-dependent response of serum lutein and macular pigment optical density to supplementation with lutein esters. Arch Biochem Biophys 2010, 504:50-55.
21. Bucheli P., Vidal K., Shen L., et al. Goji berry effects on macular characteristics and plasma antioxidant levels. Optom Vis Sci 2011, 88:257-262.
22. Thomas L.R., Toyoda Y., Delori F.C., et al. Long term dietary supplementation with zeaxanthin reduces photoreceptor in light-damaged Japanese Quail. Exp Eye Res 2002, 75:529-542.
23. Barker F.M., Snodderly D.M., Johnson E.J., et al. Nutritional manipulation of primate retinas. V: effects of lutein, zeaxanthin and n3 fatty acids on retinal sensitivity to blue light damage. Invest Ophthalmol Vis Sci 2011, 52:3934-3942.
24. Landrum J.T., Bone R.A. Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys 2001, 385:28-40.
25. Johnson E.J., Maras J.E., Rasmussen H.M., et al. Intake of lutein and zeaxanthin differ with age, sex, and ethnicity. J Am Diet Assoc 2010, 110(9):1357-1362.
26. Thomas L.R., Toyoda Y., Langner A., et al. Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. Invest Ophthalmol Vis Sci 2002, 43:3538-3549.
27. Sparrow J.R., Wu Y., Nagasaki T., et al. Fundus autofluorescence and the bisretinoids of retina. Photochem Photobiol Sci 2010, 9:1480-1489.
28. Loshin D.S., White J. Contrast sensitivity: The visual rehabilitation of the patient with macular degeneration. Arch Ophthamol 1984, 102:1303-1306.
29. Midena E., Degli Angell C., et al. Macular function impairment in eyes with early AMD. Invest Ophthalmol Vis Sci 1997, 38:469-477.
30. Haddad W.M., Souied E., Coscas G., et al. Macular pigment and age-related macular degeneration. Clinical implications. Bull Soc Belge Ophthalmol 2006, 301:15-22.
31. Carpentier S., Knaus M., Suh M. Associations between lutein, zeaxanthin, and age-related macular degeneration: an overview. Crit Rev Food Sci Nutr 2009, 49:313-326.
32. Hammond B.R., Ciulla T.A., Snodderly D.M. Macular pigment density is reduced in obese subjects. Invest Ophthalmol Vis Sci 2002, 43:47-50.
33. Kirby ML, Beatty S, Stack J, et al. Changes in macular pigment optical density and serum concentrations of lutein and zeaxanthin in response to weight loss. Br J Nutr 2011, 105:1036-1046.
34. Willett W., Sampson L., Stampfer M., et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiolol 1985, 122:51-65.
35. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study: AREDS Report #20. Arch Ophthalmol 2007, 125:671-679.
36. AREDS Report #22. Arch Ophthalmol 2007, 125:1225-1232.
37. Mayne S.T., Cartmel B., Scarmo S., et al. Noninvasive assessment of dermal carotenoids as a biomarker of fruit and vegetable intake. Am J Clin Nutr 2010, 92:794-800.
38. Chylack L. Function of the lens and methods of quantifying cataract. Nutritional and Environmental Influences on the Eye 1999, 25-52. CRC Press, Boca Raton. A. Taylor (Ed.).
39. Revicki D.A., Rentz A.M., Harnam N., et al. Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2010, 51:712-717.
40. Murray I.J., Carden D., Makridaki M. The repeatability of the MPS 9000 macular pigment screener. Br J Ophthalmol 2011, 95:431-432.
41. Van der Veen R.L.P., Berendschot T.J.M., Hendrikse F., et al. A new desktop instrument for measuring macular pigment optical density based on a novel technique for setting flicker thresholds. Ophthal Physiol Opt 2009, 29:127-137.
42. Makridaki M., Carden D., Murray I.J. Macular pigment measurement in clinics; controlling the effect of the ageing media. Ophthal Physiol Opt 2009, 29:1-7.
43. Beatty S., van Kuijk F.J., Chakravarthy U. Macular pigment and age-related macular degeneration: longitudinal data and better techniques of measurement are needed. Invest Ophthalmol Vis Sci 2008, 49:843-845.
44. Sasamoto Y., Gomi F., Sawa M., et al. Effect of cataract in evaluation of macular pigment optical density using autofluorescence spectrometry. Invest Ophthalmol Vis Sci 2011, 52:927-932.
45. Sharifzadeh M., Bernstein P.S., Gellermann W. Nonmydriatic fluorescence-based quantitative imaging of human macular pigment distributions. J Opt Soc Am A 2006, 23:2373-2387.
46. Schmitz-Valckenberg S., Fleckenstein M., Scholl H.P., et al. Fundus autofluorescence and progression of age-related macular degeneration. Surv Ophthalmol 2009, 54:96-117.
47. Bindewald A., Bird A.C., Dandekar S.S., et al. Classification of fundus autofluorescence patterns in early age-related macular disease. Invest Ophthalmol Vis Sci 2005, 46:3309-3314.
48. Retina Foundation of the Southwest. Jennie and Henry Jones Macular Function Laboratory. Available at: Accessed September 27, 2011. http://www.retinafoundation.org.
49. Wang Y.Z., Ying G.-S., Mitzel G., et al. Sensitivity and specificity of shape discrimination hyperacuity for differentiating exudative AMD from moderate AMD. Invest Ophthalmol Vis Sci 2011, 52. E-Abstract 100.
50. Arden G.B., Gunduz K., Perry S. Colour vision testing with a computer graphics system; preliminary results. Doc Ophthalmol 1988, 69:167-174.
51. Sivagnanavel V., Madill S.A., Arden G.B., et al. Correlation of colour contrast sensitivity with stage of age related macular degeneration. Invest Ophthalmol Vis Sci 2005, 46. E-Abstract 1398.
52. Wong R., Khan J., Adewoyin T., et al. The chroma test, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study. BMC Ophthalmol 2008, 8:15.
53. Schneck M.E., Haegerström-Portnoy G. Practical assessment of vision in the elderly. Ophthalmol Clin North Am 2003, 16:269-287.
54. Loshin D.S., White J. Contrast sensitivity: the visual rehabilitation of the patient with macular degeneration. Arch Ophthalmol 1984, 102:1303-1306.
55. Margrain T.H., Thomson D. Sources of variability in the clinical photostress test. Ophthal Physiol Opt 2002, 2261-2267.
56. SimulEyes® Macular Field. Available at: Last accessed March 14, 2011. http://www.simuleyes.com/index.cfm?fuseaction=content.display%26pageID=2.
57. Stiles WR, Richer SP, Cho J, et al. SD OCT retinal thinning is accelerated in early AMD and associated with CSF visual decline, Poster #2784. Presented at: The Association for Research in Vision and Ophthalmology Meeting; Ft Lauderdale, Florida; May 4, 2010.
58. Richer SP, Stiles WR, Levin MR, et al. The zeaxanthin and visual function study in atrophic age related macular degeneration (ZVF-FDA IND #78, 973) - MP and foveal shape discrimination data, Poster #510. Presented at: The Association for Research in Vision and Ophthalmology Meeting; Ft Lauderdale, Florida; May 2, 2010.
59. Wood S, Mastaloudis A, Carlson J, et al. Consistency of correlations of serum and skin carotenoids as measured by high performance liquid chromatography and raman spectroscopy. Presented at: The 15th International Symposium of Carotenoids; Okinawa, Japan; June 22-27, 2008.
60. Loane E., Nolan J.M., Beatty S. The respective relationships between lipoprotein profile, macular pigment optical density, and serum concentrations of lutein and zeaxanthin. Invest Ophthalmol Vis Sci 2010, 51:5897-5905.
61. Bernstein P. New developments in carotenoids research. Presented at: The Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University; Boston, Massachusetts; March 11-12, 2011.
62. Peralta E, Olk RJ, Sayegh Si. Oral zeaxanthin improves anatomic and visual outcome of triple therapy for subfoveal CNV in Age-related Macular Degeneration (ARMD). Presented at: The American Society of Retinal Specialists 2011 Meeting; Boston, Massachusetts; August 24, 2011.
63. Sunnes J., et al. Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology 2008, 115:1480-1488.
64. Delcourt C., Carrière I., Delage M., et al. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. Invest Ophthalmol Vis Sci 2006, 47:2329-2335.
65. Baum S.J. The accord eye study. N Eng J Med 2010, 363:22.
66. Nolan J.M., Stack J., O'Donovan O., et al. Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. Exp Eye Res 2007, 84:61-74.
67. O'Connell E.D., Nolan J.M., Stack J., et al. Diet and risk factors for age-related maculopathy. Am J Clin Nutr 2008, 87:712-722.
68. Mares J.A., Voland R.P., Sherie A., et al. Healthy lifestyles related to subsequent prevalence of age-related macular degeneration. Arch Ophthalmol 2011, 129:470-480.
69. Tan J.S., Wang J.J., Flood V., et al. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmol 2008, 115:334-341.
70. Gale C.R., Hall N.F., Phillips D.I., et al. Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci 2003, 44:2461-2465.
71. Rein D.B., et al. Forecasting age-related macular degeneration through the year 2050. Ophthalmol 2009, 127:533-540.